Cargando…
A randomized double-blind placebo-controlled trial to evaluate the value of a single bolus intravenous alfentanil in CT colonography
BACKGROUND: Although CT colonography is a less invasive alternative for colonoscopy for the detection of colorectal polyps and cancer, procedural pain is common. In several studies, CT colonography pain and burden is higher than in colonoscopy. Apart from discomfort, anxiety and its related stress-i...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3339326/ https://www.ncbi.nlm.nih.gov/pubmed/22111658 http://dx.doi.org/10.1186/1471-230X-11-128 |
_version_ | 1782231337287024640 |
---|---|
author | Boellaard, Thierry N van der Paardt, Marije P Eberl, Susanne Hollmann, Markus W Stoker, Jaap |
author_facet | Boellaard, Thierry N van der Paardt, Marije P Eberl, Susanne Hollmann, Markus W Stoker, Jaap |
author_sort | Boellaard, Thierry N |
collection | PubMed |
description | BACKGROUND: Although CT colonography is a less invasive alternative for colonoscopy for the detection of colorectal polyps and cancer, procedural pain is common. In several studies, CT colonography pain and burden is higher than in colonoscopy. Apart from discomfort, anxiety and its related stress-induced peri- procedural side effects, this may influence the adherence for CT colonography as a possible screening tool for colorectal cancer. We hypothesize that a single bolus intravenous alfentanil will give a clinically relevant reduction in maximum pain defined as at least 1.3 point reduction on an 11-point numeric rating scale (NRS). METHODS/DESIGN: A randomized double-blind placebo-controlled trial in which patients scheduled for elective CT colonography in a single tertiary centre are eligible for inclusion. The first 90 consenting patient will be block-randomized to either the alfentanil group or the placebo group. Before bowel insufflation, the alfentanil group receives a single bolus intravenous alfentanil 7.5 μg/kg dissolved in 0.9% NaCl, while the placebo group receives an intravenous bolus injection of pure 0.9% NaCl. For both groups an equal amount of fluid per kilogram (75 μL/kg) is injected. The primary outcome is the difference in maximum pain on an 11-point NRS. Secondary outcomes include: pain and burden of different CT colonography aspects, side effects, procedural time and recovery time. For the primary outcome an independent samples t-test is performed and a P value < 0.05 is considered statistically significant. DISCUSSION: This study will provide evidence whether a single bolus intravenous alfentanil gives a clinically relevant reduction in maximum pain during CT colonography. TRIAL REGISTRATION: Netherlands Trial Register (NTR): NTR2902 This trial will be conducted in accordance with the protocol and in compliance with the moral, ethical, and scientific principles governing clinical research as set out in the Declaration of Helsinki (1989) and Good Clinical Practice (GCP). The department of radiology of the Academic Medical Center of Amsterdam is responsible for the design and conduct of the trial. |
format | Online Article Text |
id | pubmed-3339326 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-33393262012-05-01 A randomized double-blind placebo-controlled trial to evaluate the value of a single bolus intravenous alfentanil in CT colonography Boellaard, Thierry N van der Paardt, Marije P Eberl, Susanne Hollmann, Markus W Stoker, Jaap BMC Gastroenterol Study Protocol BACKGROUND: Although CT colonography is a less invasive alternative for colonoscopy for the detection of colorectal polyps and cancer, procedural pain is common. In several studies, CT colonography pain and burden is higher than in colonoscopy. Apart from discomfort, anxiety and its related stress-induced peri- procedural side effects, this may influence the adherence for CT colonography as a possible screening tool for colorectal cancer. We hypothesize that a single bolus intravenous alfentanil will give a clinically relevant reduction in maximum pain defined as at least 1.3 point reduction on an 11-point numeric rating scale (NRS). METHODS/DESIGN: A randomized double-blind placebo-controlled trial in which patients scheduled for elective CT colonography in a single tertiary centre are eligible for inclusion. The first 90 consenting patient will be block-randomized to either the alfentanil group or the placebo group. Before bowel insufflation, the alfentanil group receives a single bolus intravenous alfentanil 7.5 μg/kg dissolved in 0.9% NaCl, while the placebo group receives an intravenous bolus injection of pure 0.9% NaCl. For both groups an equal amount of fluid per kilogram (75 μL/kg) is injected. The primary outcome is the difference in maximum pain on an 11-point NRS. Secondary outcomes include: pain and burden of different CT colonography aspects, side effects, procedural time and recovery time. For the primary outcome an independent samples t-test is performed and a P value < 0.05 is considered statistically significant. DISCUSSION: This study will provide evidence whether a single bolus intravenous alfentanil gives a clinically relevant reduction in maximum pain during CT colonography. TRIAL REGISTRATION: Netherlands Trial Register (NTR): NTR2902 This trial will be conducted in accordance with the protocol and in compliance with the moral, ethical, and scientific principles governing clinical research as set out in the Declaration of Helsinki (1989) and Good Clinical Practice (GCP). The department of radiology of the Academic Medical Center of Amsterdam is responsible for the design and conduct of the trial. BioMed Central 2011-11-23 /pmc/articles/PMC3339326/ /pubmed/22111658 http://dx.doi.org/10.1186/1471-230X-11-128 Text en Copyright ©2011 Boellaard et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Study Protocol Boellaard, Thierry N van der Paardt, Marije P Eberl, Susanne Hollmann, Markus W Stoker, Jaap A randomized double-blind placebo-controlled trial to evaluate the value of a single bolus intravenous alfentanil in CT colonography |
title | A randomized double-blind placebo-controlled trial to evaluate the value of a single bolus intravenous alfentanil in CT colonography |
title_full | A randomized double-blind placebo-controlled trial to evaluate the value of a single bolus intravenous alfentanil in CT colonography |
title_fullStr | A randomized double-blind placebo-controlled trial to evaluate the value of a single bolus intravenous alfentanil in CT colonography |
title_full_unstemmed | A randomized double-blind placebo-controlled trial to evaluate the value of a single bolus intravenous alfentanil in CT colonography |
title_short | A randomized double-blind placebo-controlled trial to evaluate the value of a single bolus intravenous alfentanil in CT colonography |
title_sort | randomized double-blind placebo-controlled trial to evaluate the value of a single bolus intravenous alfentanil in ct colonography |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3339326/ https://www.ncbi.nlm.nih.gov/pubmed/22111658 http://dx.doi.org/10.1186/1471-230X-11-128 |
work_keys_str_mv | AT boellaardthierryn arandomizeddoubleblindplacebocontrolledtrialtoevaluatethevalueofasinglebolusintravenousalfentanilinctcolonography AT vanderpaardtmarijep arandomizeddoubleblindplacebocontrolledtrialtoevaluatethevalueofasinglebolusintravenousalfentanilinctcolonography AT eberlsusanne arandomizeddoubleblindplacebocontrolledtrialtoevaluatethevalueofasinglebolusintravenousalfentanilinctcolonography AT hollmannmarkusw arandomizeddoubleblindplacebocontrolledtrialtoevaluatethevalueofasinglebolusintravenousalfentanilinctcolonography AT stokerjaap arandomizeddoubleblindplacebocontrolledtrialtoevaluatethevalueofasinglebolusintravenousalfentanilinctcolonography AT boellaardthierryn randomizeddoubleblindplacebocontrolledtrialtoevaluatethevalueofasinglebolusintravenousalfentanilinctcolonography AT vanderpaardtmarijep randomizeddoubleblindplacebocontrolledtrialtoevaluatethevalueofasinglebolusintravenousalfentanilinctcolonography AT eberlsusanne randomizeddoubleblindplacebocontrolledtrialtoevaluatethevalueofasinglebolusintravenousalfentanilinctcolonography AT hollmannmarkusw randomizeddoubleblindplacebocontrolledtrialtoevaluatethevalueofasinglebolusintravenousalfentanilinctcolonography AT stokerjaap randomizeddoubleblindplacebocontrolledtrialtoevaluatethevalueofasinglebolusintravenousalfentanilinctcolonography |